DUBLIN – ADC Therapeutics Sarl, an emerging powerhouse in the development of antibody-drug conjugates (ADCs) for cancer, has made its first clinical data disclosures in hematological malignancies, which will propel the company into the heart of the battle for supremacy against both developers of ADCs and of chimeric antigen receptor (CAR) T-cell therapies.